@dido2
Some clarifications on “Mycoplasma pneumonia”:
Mycoplasma Pneumonia

Mycoplasma pneumonia is a form of atypical bacterial (not viral) pneumonia caused by Mycoplasma pneumoniae, one of the smallest free-living organisms known. It's sometimes called "walking pneumonia" because symptoms are often mild enough that people remain ambulatory and may not realize they have pneumonia.

Key Characteristics:
The organism — M. pneumoniae is notable for lacking a cell wall, which distinguishes it from most other bacteria. This has important clinical implications: common antibiotics like penicillin that target cell wall synthesis are ineffective, while macrolides (e.g., azithromycin), tetracyclines, and fluoroquinolones are typically used instead.

Epidemiology
Accounts for roughly 10–40% of community-acquired pneumonia cases, with higher proportions in outbreaks
Occurs worldwide, with epidemic peaks every 3–7 years
Most common in older children and young adults (ages 5–40), though all ages can be affected
Spreads via respiratory droplets; incubation period is typically 1–4 weeks

Clinical Presentation
Symptoms often develop gradually and can include:
Persistent dry cough (often the hallmark symptom)
Low-grade fever
Fatigue and malaise
Sore throat
Headache
Ear pain (myringitis can occur)
Chest auscultation may reveal crackles or wheezing, but physical exam findings are often disproportionately mild compared to radiographic evidence — a classic feature of atypical pneumonia.

Diagnosis
Chest X-ray may show patchy or interstitial infiltrates, often more extensive than symptoms suggest
PCR testing on respiratory specimens is the most sensitive and specific method
Serology (IgM/IgG antibodies) can support diagnosis but has limitations with timing
Cold agglutinin titers are nonspecific but historically associated

Complications
While usually self-limiting, M. pneumoniae infections can lead to:
Extrapulmonary manifestations: skin rashes (erythema multiforme), neurological complications (encephalitis, Guillain-Barré syndrome), hemolytic anemia, cardiac involvement
Severe pneumonia requiring hospitalization, particularly in immunocompromised individuals
Post-infectious bronchiolitis obliterans (rare but serious)

Treatment
First-line therapy is typically a macrolide antibiotic (azithromycin being most commonly prescribed). Tetracyclines (doxycycline) and fluoroquinolones are alternatives, particularly in adults. Rising macrolide resistance has been documented in several regions, especially parts of Asia, which can complicate treatment.